Health Briefing: Personalised Vaccine Passes Early Ovarian Cancer Test Newsletter Industry News October 16, 2026 Our health briefing: a personalised neoantigen vaccine combined with nivolumab proved feasible and acceptably safe in an early ovarian cancer trial.
